been trialled including nandrolone (Gardner & Besa, ; Besa et al , ), testosterone (Silver et al , ; Gardner & Besa, ; Besa et al , ), fluoxymesterone (Gardner & Besa, ; Brubaker et al , ), oxymethalone (Alexanian et al , ; Gardner & Besa, ; Hast et al , ), etiocholanolone (Gardner & Besa, ) and danazol (Levy et al , ; Cervantes et al , , ). Response rates to androgen therapy are reported as varying